USPTO serial 85876328
CANCER
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- HELFMAN, JUDITH MICHELLE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CANCER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Camille M. Miller
CAMILLE M. MILLER COZEN O'CONNOR1650 MARKET STOne Liberty PlacePHILADELPHIA, PA 19103-3527Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of certain blood diseases and cancers | ACTIVE | — |
| 042 | Development and testing services in the fields of biotechnology, chemistry and pharmaceuticals; scientific study and research in the fields of the prevention, treatment and management of illness, health care delivery and the scientific aspects of health care policy, health care cost management and financing as these fields impact on quality of health care; research in the fields of chemicals and pharmaceuticals; research and testing services in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; providing clinical laboratory testing services for medical and scientific research and development purposes, namely, pharmacogenetic testing, predictive medical testing, personalized medical testing, gene sequencing-based testing and genotyping based on the assessment, development and application of genomic discoveries in the pharmaceutical, informatics and clinical diagnostic industries; scientific research services; scientific research, namely, development of pharmaceuticals or diagnostic methods for others | ACTIVE | — |
| 044 | Providing on-line information in the field of diagnosis and treatment of cancer; providing an on-line computer database featuring information relating to diagnosis and treatment of cancer; providing medical and pharmaceutical information services; providing links to web sites of others featuring information about the diagnosis and treatment of cancer; providing medical information and pharmaceutical information services, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; disease management programs that provide counseling and information in the field of pharmaceuticals, and distributing written materials in connection therewith; providing an interactive website featuring medical information that enables users to enter, access, track, monitor and generate health and medical information and reports; providing pharmacogenetic testing, predictive medical testing, personalized medical testing, gene sequencing-based testing and genotyping, all for medical diagnostic and treatment purposes, based on the assessment, development and application of genomic discoveries in the pharmaceutical, informatics and clinical diagnostic industries | ACTIVE | — |
| 045 | Government pharmaceutical programs that provide counseling and information to medical professionals, pharmacists and patients, including counseling and information on consumer product safety issues pertaining to pharmaceuticals, and distributing printed materials in connection therewith | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Celgene Corporation
- Other trademarks owned by Celgene Corporation
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named CANCER
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 12, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 12, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 22, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 21, 2016 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Dec 29, 2015 | EXT5 | SOU EXTENSION 5 FILED | — |
| Dec 29, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 28, 2015 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 10, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 9, 2015 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 30, 2015 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 30, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 27, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 26, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 5, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 5, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 6, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 5, 2014 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 5, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 8, 2014 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 8, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 9, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 7, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 7, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 6, 2013 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 11, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 11, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 22, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 4, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 4, 2013 | ALIE | ASSIGNED TO LIE | — |
| Apr 24, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 24, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 24, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 24, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2013 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 24, 2013 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 24, 2013 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Apr 24, 2013 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Apr 23, 2013 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 23, 2013 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 23, 2013 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Apr 23, 2013 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Apr 17, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2013 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 20, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 18, 2013 | NWAP | NEW APPLICATION ENTERED | — |